Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort

Conclusion
Phase I of GLORIA-AF shows that VKAs were mostly used in patients with persistent/permanent (vs. paroxysmal) AF and in those with high stroke risk. Furthermore, there were meaningful geographical differences in the use of VKA therapy in the era before the availability of NOACs, including a much lower use of VKAs in China, where most patients either received antiplatelet agents or no antithrombotic treatment.

Source: Europace - August 30, 2016 Category: Cardiology Authors: Huisman, M. V., Ma, C. S., Diener, H.-C., Dubner, S. J., Halperin, J. L., Rothman, K. J., Teutsch, C., Schoof, N., Kleine, E., Bartels, D. B., Lip, G. Y. H., for the GLORIA-AF Investigators Tags: Atrial fibrillation Source Type: research